Jefferies Financial Group initiated coverage on shares of Zai Lab (NASDAQ:ZLAB) in a report issued on Wednesday, Marketbeat reports. The brokerage issued a buy rating on the stock.
A number of other equities research analysts have also recently commented on the stock. BidaskClub cut shares of Zai Lab from a hold rating to a sell rating in a report on Friday, September 7th. Zacks Investment Research cut shares of Zai Lab from a hold rating to a sell rating in a report on Wednesday, September 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $34.00.
Shares of NASDAQ:ZLAB opened at $17.19 on Wednesday. Zai Lab has a one year low of $14.29 and a one year high of $27.34.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More: Index Funds
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.